Bendell Takes the Helm as Chief Development Officer at Sarah Cannon

March 22, 2018

Internationally renowned expert, Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.

Johanna C. Bendell, MD

Internationally renowned expert,Johanna C. Bendell, MD, has been promoted to chief development officer at Sarah Cannon. Her title responsibilities include developing and expanding physician, site, and Pharma relationships across the Sarah Cannon Network, thereby expanding the organization’s efforts to bring more qualitative treatment options to its patients.

As noted in a statement by Howard A. Burris III, MD, president of clinical operations and chief of medical officer for Sarah Cannon, “…it is important to capitalize on Johanna’s experience to further our mission of advancing therapies for patients. Under her leadership, we look forward to continuing to enhance access to the latest treatments for people facing cancer in communities across the United States and United Kingdom.”

In addition to her new position, Bendell will continue serving as director of the Gastrointestinal (GI) Cancer Research Program, where she oversees the clinical trial offerings and designs for GI cancers throughout the expansive network at Sarah Cannon. She has also served as associate director of the Drug Development Program at Sarah Cannon Research Institute, since joining Sarah Cannon in 2006.

Prior to Sarah Cannon, Bendell was an assistant of medicine at Massachusetts General Hospital and an instructor in medicine at Harvard Medicine School. She later joined Duke University as an assistant professor specializing in GI cancers and phase I research.

Her research focuses on early drug development of primarily targeted agents and has help to guide the first-in-man agents to proof-of-concept studies. As chief development officer, Bendell will collaborate with the additional leaders of Sarah Cannon Development Innovations, the organization’s contract research organization, and clinical operations teams to provide optimal physician leaders to these lines of work.